DAT-delivered astaxanthin reprograms adipogenesis through RhoGDI1 dephosphorylation at Ser174 and RhoA/FAK/ERK1/2 cascade suppression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41506140.
- Also identified by DOI 10.1016/j.biomaterials.2026.123979.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adipose tissue serves as a primary approach for soft tissue defect repair, but clinical regeneration remains limited by inadequate adipogenic capacity. While astaxanthin (AST) can ameliorate adipose dysfunction, the underlying mechanisms governing its pro-adipogenic activity remain elusive. Here, we developed an AST-loaded decellularized adipose tissue (DAT) hydrogel with the aim of boosting adipogenic potential. Subcutaneous implantation of DAT-AST hydrogel into rabbit inguinal fat pad defects significantly enhanced adipogenesis and tissue restoration. In human adipose-derived stem cells (ADSCs), astaxanthin significantly promoted the adipogenic differentiation by suppressing phosphorylation of RhoGDI1 at Ser174 - a newly identified AST-binding target. RhoGDI1 knockdown abolished AST-induced lipid accumulation and disrupted RhoGDI1 related signaling axis (RhoA/FAK/ERK1/2), demonstrating that RhoGDI1 dephosphorylation is essential for AST's pro-adipogenic action. Collectively, this work reveals a targetable pathway for adipose regeneration and establishes DAT as a promising delivery platform for AST therapeutics.
Medical subject headings
- Adipogenesis
- Adipose Tissue
- MAP Kinase Signaling System